Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

NCT ID: NCT02009644

Last Updated: 2026-01-28

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 158 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-11-23
• Study Completion Date: 2026-06-30

Brief Summary

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).

Detailed Description

This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. Upon completion of enrollment of150 subjects, an additional 50 subjects may be treated with the Treovance Stent-Graft at the 30 investigative sites participating in the trial. These additional subjects will follow the same study schedule, and data from these patients may be used to supplement the pivotal trial data. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted. Subjects with fracture(s) confirmed by the Core Lab within the first 5 years will be followed for an additional 5 years, for a total of 10 years post-implantation.

The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S.

There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms:

• Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant
• Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days

Secondary objectives involve assessment of major device-related events and major morbidity.

Conditions

Abdominal Aortic Aneurysm (AAA)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treovance

Subjects who receive the Treovance stent-graft

Group Type: EXPERIMENTAL

Subjects who receive the Treovance stent-graft

Intervention Type: DEVICE

Eligible subjects will be implanted with the Treovance Stent-Graft

Interventions

Subjects who receive the Treovance stent-graft

Eligible subjects will be implanted with the Treovance Stent-Graft

Intervention Type: DEVICE

Other Intervention Names

Treovance Abdominal Stent-Graft with Navitel Delivery System

Eligibility Criteria

Inclusion Criteria

1. Subject must be between the ages of 18 and 85

2. Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement, by CT with contrast performed within 4 months of planned implant procedure

3. Subject must have an infrarenal AAA that i. is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or ii. has increased in diameter by 0.5 cm in the last 6 months

4. Subject must have i. infrarenal landing neck length of 10 mm or greater and an angle of less than 60 degrees relative to the long axis of the aneurysm (centerline at lowest renal to centerline at bifurcation) and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 17 mm -32 mm, or ii. infrarenal landing neck length of 15 mm or greater and an angle of between 60 and 75 degrees relative to the long axis of the aneurysm and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 16 mm-30 mm

5. Subject's infrarenal landing neck must meet the vessel size requirements specified in the instructions for use (IFU) for the corresponding devices

6. Subject must have lowest renal artery at least 9 cm from the aortic bifurcation

7. Subject must have a distal iliac landing neck with i. an inside diameter of 8 mm - 13 mm and a length of at least 10 mm, or ii. an inside diameter of >13 mm - 20 mm and a length of at least 15 mm

8. Subject's distal iliac landing neck must meet the vessel size requirements specified for the corresponding devices in the IFU

9. Subject must have a total treatment length of at least 13 cm

10. Subject must have a distal aortic diameter above the iliac bifurcation equal to or greater than 70% of the sum of the selected leg graft diameters that will pass through the same

11. Subject must be willing and able to comply with 1-month, 6-month, and 12-month follow-up visits, as well as annual visits out to 5 years

12. Subject must have adequate renal function to tolerate required follow-up contrast-enhanced CTs

13. Subject must have adequate vascular access (e.g., patent iliac or femoral arteries) for introduction of the Navitel Delivery System, which is 18F (6 mm) or 19F (6.3 mm) outer diameter based on size of device used. Alternatively, subject's anatomy is suitable for creation of an iliac conduit.

14. Subject or Legally Authorized Representative (LAR) must agree to sign Informed Consent Form

Exclusion Criteria

1. Subject is pregnant or lactating

2. Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)

3. Subject has a patent inferior mesenteric artery that cannot be sacrificed and an occluded or stenotic celiac and/or superior mesenteric artery

4. Implant procedure as planned does not allow for at least one patent hypogastric artery left intact, unless both are occluded on pre-op imaging

5. Subject has a lesion that cannot be crossed by a guide wire

6. Proximal neck cannot increase by more than 10% over 15mm or more than 7% over 10mm; i.e., no trapezoidal necks

7. Subject has severe untreated coronary artery disease and/or unstable angina, significant areas of myocardium at risk (based on coronary angiogram or radionuclide scans), left ventricular ejection fraction < 20%, or recent diagnosis of Congestive Heart Failure (CHF)

8. Subject has had a stroke or myocardial infarction within 6 months of the planned treatment date

9. Subject has chronic obstructive pulmonary disease requiring routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use)

10. Subject has an active systemic infection or is suspected of having an active systemic infection (e.g.,AIDS/HIV, sepsis)

11. Subject is morbidly obese (more than 100% over the ideal body weight or as defined by institutional standards) or has other clinical conditions that severely compromise or impair x-ray visualization of the aorta

12. Subject has connective tissue disease (e.g., Marfan's syndrome)

13. Subject has a mycotic aneurysm

14. Subject has significant or circumferential calcification or mural thrombus in the proximal aortic neck

15. Subject has significant or circumferential calcification or mural thrombus in the distal iliac landing zone

16. Subject has significant or circumferential calcification or mural thrombus within the treatment length, which may adversely impact device patency

17. Subject has a blood coagulation disorder or bleeding diathesis, the treatment for which cannot be suspended pre- and post-repair

18. Subject is in acute or chronic renal failure (creatinine > 2.5 mg/dL) unless subject is stable on dialysis

19. Subject has less than two-year life expectancy as evidenced by factors prohibiting major medical intervention (e.g., presence of malignancy, severe cardiopulmonary disease, etc.)

20. Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure

21. Subject is confronted with other medical, social or psychological issues that the investigator believes may interfere with study treatment or follow-up. These reasons must be documented. An example may include adherence to a theological or personal doctrine with aversion or opposition to blood transfusion.

22. Subject has had a prior AAA repair (endovascular or surgical)

23. Subject has an untreatable allergy or sensitivity to contrast media, nitinol/nickel, or polyester

24. Subject has undergone other major surgical or medical intervention within 45 days of the planned procedure or is planning to undergo other major surgical or medical intervention within 45 days post implantation (e.g., Coronary Artery Bypass Graft (CABG), organ transplantation, renal stenting, etc.)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bolton Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Matthew Eagleton, MD

Role: PRINCIPAL_INVESTIGATOR

Cleveland Clinic Foundaton

Locations

University of Alabama-Birmingham

Birmingham, Alabama, United States

Arizona Heart Institute

Phoenix, Arizona, United States

Danbury Hospital

Danbury, Connecticut, United States

Lynn Heart and Vascular Institute

Boca Raton, Florida, United States

Northside Hospital Heart & Vascular Institute

Atlanta, Georgia, United States

Presence Medical Center -- Christie Clinic

Champaign, Illinois, United States

University of Chicago

Chicago, Illinois, United States

Affiliated Surgeons of Rockford Memorial Hospital

Rockford, Illinois, United States

University of Iowa Hospital and Clinic

Iowa City, Iowa, United States

Tufts University Medical Center

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Massachusetts

Worcester, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Community Care (previously Albany Medical Center)

Albany, New York, United States

Buffalo General Medical Center

Buffalo, New York, United States

Mount Sinai Medical Center

New York, New York, United States

University of Rochester -- Strong Memorial Hospital

Rochester, New York, United States

Stony Brook Medical Center

Stony Brook, New York, United States

Mission Hospital

Asheville, North Carolina, United States

East Carolina University / Pitt County Memorial Hospital

Greenville, North Carolina, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

The Ohio State University

Columbus, Ohio, United States

Temple University School of Medicine

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

York Hospital

York, Pennsylvania, United States

Rhode Island Hospital

Providence, Rhode Island, United States

North Central Heart (Avera Heart Hospital)

Sioux Falls, South Dakota, United States

Sanford University of South Dakota Medical Center

Sioux Falls, South Dakota, United States

Sentara Vascular Specialists

Norfolk, Virginia, United States

Countries

United States

Other Identifiers

IP-0008-12

Identifier Type: -

Identifier Source: org_study_id